Abstract
The design and synthesis of a series of tripeptide acylsulfonamides as potent inhibitors of the HCV NS3/4A serine protease is described. These analogues house a C4 aryl, C4 hydroxy-proline at the S2 position of the tripeptide scaffold. Information relating to structure-activity relationships as well as the pharmacokinetic and cardiovascular profiles of these analogues is provided.
Keywords:
C4 aryl, C4 hydroxy-proline; Cardiovascular profiles; HCV NS3/4A serine protease inhibitors; Potent and orally bioavailable; Tripeptide acylsulfonamides.
Copyright © 2016 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antiviral Agents / chemistry*
-
Antiviral Agents / pharmacokinetics
-
Antiviral Agents / pharmacology
-
Half-Life
-
Heart / drug effects
-
Hepacivirus / drug effects
-
Hepacivirus / enzymology*
-
Humans
-
In Vitro Techniques
-
Oligopeptides / chemistry*
-
Oligopeptides / pharmacokinetics
-
Oligopeptides / pharmacology
-
Proline / chemistry
-
Protease Inhibitors / chemistry*
-
Protease Inhibitors / pharmacokinetics
-
Protease Inhibitors / pharmacology
-
Rabbits
-
Rats
-
Structure-Activity Relationship
-
Sulfonamides / chemistry
-
Viral Nonstructural Proteins / antagonists & inhibitors*
-
Viral Nonstructural Proteins / metabolism
Substances
-
Antiviral Agents
-
NS3 protein, hepatitis C virus
-
Oligopeptides
-
Protease Inhibitors
-
Sulfonamides
-
Viral Nonstructural Proteins
-
Proline